Abterra Biosciences began life as Digital Proteomics LLC, a spin-out of the University of California San Diego - currently resident in JLabs San Diego - delivers cutting-edge computational solutions to the proteomics community. Utilizing algorithmic and machine learning approaches, the firm's personnel are enabling effective and efficient drug discovery / development of efficient, effective tools to address core bioinformatics problems. Digital Proteomics creates high performance analytic and software tools designed to advance discovery and development in therapeutics and health and - be extnsion - removing bottlenecks in drug discovery. Antibodies, for example, are a rapidly growing class of therapeutics across a range of indications, including oncology, immunology, and infectious diseases. Antibody therapeutics were previously developed primarily in rodents and then humanized. The shift has been to have antibody therapeutics becomed more human. The premise is tht. despite the success of human antibodies as therapeutics, the natural human immune system has been underutilized as a source of therapeutic candidates. Humans survive a wide range of immunological challenges and produce antibodies that were crucial in overcoming the illness. Digital Proteomics personnel have developed Alicanto® to discover antibodies from survivors to develop into therapeutics
